Figure EV5. Partial rescue of the IgG response and GC formation by HSPC therapy.

1. Chimerism of WT and Cd40lg ^−/− cells observed within CD11b⁺ myeloid cells at long‐term follow‐up after transplant in PB of mice from Fig 7A (n = 21 100% WT, 8 25% WT, 22 10% WT, 14 1% WT, 22 0% WT). Three independent experiments. Mean ± SEM.
2. Chimerism of WT and Cd40lg ^−/− cells observed within CD19⁺ B cells, CD4⁺ T cells, CD8⁺ T cells and CD11b⁺ myeloid cells at the end of the experiment in PB (upper panel) (n = 20 100% WT, 6 25% WT, 21 10% WT, 14 1% WT, 21 0% WT) or spleen (lower panel) (n = 18 100% WT, 6 25% WT, 19 10% WT, 13 1% WT, 20 0% WT) of mice from Fig 7A. Three independent experiments. Mean ± SEM.
3. OVA‐specific IgG concentration in sera of mice from Fig 7A collected 7 days before (pre) and after (post) OVA booster immunization (n = 4 100% WT, 5 10% WT, 4 1% WT, 4 0% WT). Median ± IQR.
4. Representative plots showing the gating strategy used to characterize B220⁺PNAhigh GC B‐cell percentages from Fig 7A within each experimental group. Splenic mononuclear cells were stained with B220, CD19, PNA, and GL7. PNA⁺GL7⁺ GC B cells are derived from B220⁺CD19⁺ gated splenocytes.